Ainos Corp (AIMD) - Market Value to Book Value Ratio

Corporate emblem and logo of Ainos (AIMD)

Ainos, Inc. (AIMD) faces significant challenges in bringing portable systems to market, trailing tech giants in sales volumes. Meanwhile, the business relies on a digital breath analysis platform integrated with cloud services for the rapid detection of infections. The current metric stands at 1.81. The company's price chart confirms the potential synergy of digital diagnostics created through partnerships with telemedicine software developers.

Ainos Corporation (AIMD) - Market-to-Book Ratio from 04/28/2023 to 10/29/2026
Flagship merchandise of Ainos Corp

Professional capital evaluates Ainos, Inc. (AIMD) through the lens of intellectual assets and expansion rates. This indicator compares current market value with net assets, identifying whether the market is paying a premium for future growth or if the business is undervalued. An analysis of the company's valuation relative to its book value demonstrates a premium for its innovative potential. The high multiple here is driven by the recruitment of elite IT talent and biochemists, confirming the market's bet on the issuer's patent strategy.

Competitor analysis

A: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio DGX|Market Value to Book Value Ratio Illumina|Market Cap to Net Assets Ratio Exact Sciences Corp (EXAS)|Market Capitalization to Book Value Ratio RVTY|BIO - Market-to-Book Ratio|Market Capitalization to Book Value Ratio NNNN (Anbio Biotechnology)|SHC: Capitalization to Book Value Ratio|QuidelOrtho Corporation - Market Capitalization to Book Value Ratio|OPK - Market Capitalization to Book Value Ratio|CareDx (CDNA) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio MRVI|FLGT (Fulgent Genetics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio fluidigm.com|Market Value to Book Value Ratio Cytek Biosciences (CTKB)|Market Value to Book Value Ratio OSUR (OraSure Technologies, Inc.)|Exagen - Market Cap to Net Assets Ratio|MDxHealth, Inc. (MDXH) - Market-to-Book Ratio|LUCD - Market Value to Book Value Ratio|Market Capitalization to Book Value Prenetics Global PRE|IMDX: Market Capitalization to Book Value Ratio|TRIB - Market Capitalization to Book Value|Market Value to Book Value Ratio ProPhase|CoDx (CODX) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio HSCS|Market Capitalization to Book Value Ratio biomerica.com (BMRA)|Market Capitalization to Book Value Ratio CDIO (Cardio Diagnostics Holdings)|Market Capitalization to Book Value Virax Biolabs Group Limited (VRAX)|BJDX - Market Value to Book Value Ratio|AWH (Aspira Women's Health Inc) - Capitalization to Book Value Ratio|Accelerate Diagnostics (AXDX) - Market Value to Book Value Ratio|Market-to-Book Ratio CENTOGENE (CNTG)|Market Value to Book Value Ratio Enzo Biochem Inc.|Fresh2 (FRES) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio GENE (Genetic Technologies)|ME (23andMe Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio PMD (Psychemedics)